Reuters logo
BRIEF-TxCell appoints Lentigen Technology to manufacture lentiviral vector for its first CAR-Treg Program in transplant rejection
June 19, 2017 / 4:26 PM / 6 months ago

BRIEF-TxCell appoints Lentigen Technology to manufacture lentiviral vector for its first CAR-Treg Program in transplant rejection

June 19 (Reuters) - TXCELL SA:

* TXCELL APPOINTS LENTIGEN TECHNOLOGY, INC. TO MANUFACTURE THE LENTIVIRAL VECTOR FOR ITS FIRST CAR-TREG PROGRAM IN TRANSPLANT REJECTION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below